Neuren Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Neuren Pharmaceuticals has a total shareholder equity of A$219.2M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$228.2M and A$9.0M respectively. Neuren Pharmaceuticals's EBIT is A$155.2M making its interest coverage ratio -14.3. It has cash and short-term investments of A$213.2M.
Key information
0%
Debt to equity ratio
AU$0
Debt
| Interest coverage ratio | -14.3x |
| Cash | AU$213.17m |
| Equity | AU$219.15m |
| Total liabilities | AU$9.00m |
| Total assets | AU$228.15m |
Recent financial health updates
Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business
Jan 07
We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
Sep 06Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth
May 31We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn
Feb 03Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation
Aug 06We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
May 05Recent updates
New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)
Nov 11Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up
Nov 08Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)
Oct 24Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models
Aug 29Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now
Aug 14Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today
May 31Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely
May 03An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued
Apr 01Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically
Mar 05Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors
Mar 02Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors
Dec 18Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues
Sep 02Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)
Aug 31This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year
Mar 03Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business
Jan 07We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
Sep 06Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth
May 31We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn
Feb 03Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation
Aug 06We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
May 05Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)
Feb 19Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?
Jan 04
Financial Position Analysis
Short Term Liabilities: NEU's short term assets (A$228.0M) exceed its short term liabilities (A$9.0M).
Long Term Liabilities: NEU's short term assets (A$228.0M) exceed its long term liabilities (A$29.0K).
Debt to Equity History and Analysis
Debt Level: NEU is debt free.
Reducing Debt: NEU has not had any debt for past 5 years.
Debt Coverage: NEU has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: NEU has no debt, therefore coverage of interest payments is not a concern.